CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective study of the safety and efficacy of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s174, 2023. DOI: 10.25251/skin.7.supp.174. Disponível em: https://skin.dermsquared.com/skin/article/view/1998. Acesso em: 19 apr. 2025.